+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID06561048

Study Comparing Oral Soquelitinib to Physicians Choice Standard Treatments in Adults with Relapsed or Refractory Peripheral T-cell Lymphoma Including Follicular Helper and Anaplastic Large-cell Types

Led by Corvus Pharmaceuticals, Inc. · Updated on 2026-09-25

150

Participants Needed

37

Research Sites

56 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the efficacy and safety of soquelitinib, an oral interleukin-2-inducible T cell kinase ITK inhibitor, compared to the physicians choice standard of care SOC treatments in adults with relapsed or refractory peripheral T-cell lymphoma not otherwise specified PTCL-NOS, follicular helper T-cell lymphomas FHTCLs, or systemic anaplastic large-cell lymphoma sALCL. This Phase 3, randomized, open-label study involves approximately 150 participants and aims to assess progression-free survival and other clinical outcomes in this population. Participants will be randomly assigned to one of two groups one receiving soquelitinib 200 mg orally twice daily, and the other receiving a physicians choice SOC treatment with either belinostat or pralatrexate. Treatments are administered for up to 2 years, or until unacceptable toxicity or disease progression occurs. Participants initially receiving SOC who experience disease progression may have the option to switch to soquelitinib treatment. During the study, participants will undergo regular assessments including imaging scans to measure disease status, lab tests to monitor organ function, and evaluations of treatment response and survival outcomes. Researchers will track progression-free survival for up to 4 years after treatment begins, along with objective response rates and overall survival up to 2 and 4 years respectively. Safety and tolerability will also be closely monitored throughout the study period.

CONDITIONS

Brief Title

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Research Team

S

Study Director

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here